MDG2 Stock Overview
A biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
Medigene AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.03 |
| 52 Week High | €5.40 |
| 52 Week Low | €1.02 |
| Beta | 0.98 |
| 1 Month Change | -36.81% |
| 3 Month Change | -51.76% |
| 1 Year Change | -64.60% |
| 3 Year Change | -82.42% |
| 5 Year Change | -87.16% |
| Change since IPO | -95.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| MDG2 | AT Biotechs | AT Market | |
|---|---|---|---|
| 7D | -8.0% | -1.3% | -0.8% |
| 1Y | -64.6% | 11.4% | -1.6% |
Return vs Industry: MDG2 underperformed the Austrian Biotechs industry which returned 11.4% over the past year.
Return vs Market: MDG2 underperformed the Austrian Market which returned -1.6% over the past year.
Price Volatility
| MDG2 volatility | |
|---|---|
| MDG2 Average Weekly Movement | 12.2% |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 3.8% |
| 10% most volatile stocks in AT Market | 6.3% |
| 10% least volatile stocks in AT Market | 2.1% |
Stable Share Price: MDG2's share price has been volatile over the past 3 months compared to the Austrian market.
Volatility Over Time: MDG2's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Austrian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 87 | Selwyn Ho | www.medigene.com |
Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company’s end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its lead product includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications.
Medigene AG Fundamentals Summary
| MDG2 fundamental statistics | |
|---|---|
| Market cap | €15.18m |
| Earnings (TTM) | -€15.93m |
| Revenue (TTM) | €7.45m |
2.0x
P/S Ratio-1.0x
P/E RatioIs MDG2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MDG2 income statement (TTM) | |
|---|---|
| Revenue | €7.45m |
| Cost of Revenue | €1.49m |
| Gross Profit | €5.95m |
| Other Expenses | €21.89m |
| Earnings | -€15.93m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.08 |
| Gross Margin | 79.94% |
| Net Profit Margin | -213.98% |
| Debt/Equity Ratio | 0% |
How did MDG2 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 12:45 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Medigene AG is covered by 9 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Xian Deng | Berenberg |
| Gary Waanders | Bryan Garnier & Co |
| Thibaud Rutsaert | GSN North America |